Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C

Digestive Diseases and Sciences

Volumn 48, Issue 1, 2003, Pages 140-145

  Theodore, Dickens ^a   Shiffman, Mitchell L ^b   Sterling, Richard K ^b   Bruno, Christine J ^c   Weinstein, Jeffrey ^d   Crippin, Jeffrey S ^d   Garcia, Gabriel ^e   Wright, Teresa L ^f   Conjeevaram, Hari ^g   Reddy, Rajender K ^h   Nolte, Frederick S ^c   Fried, Michael W ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d BAYLOR UNIVERSITY   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF MIAMI   (United States)

Author keywords

African American; Hepatitis C; Interferon; Race; Therapy

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; DOSE RESPONSE; DRUG MEGADOSE; ETHNIC GROUP; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; VIRUS DETECTION;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0037283618     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021750818611     Document Type: Article

References (20)

1. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30:787-793, 1999
2. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J: The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 119:1317-1323, 2000
3. Howell C, Jeffers L, Hoofnagle JH: Hepatitis C in African Americans: Summary of a workshop. Gastroenterology 119:1385-1396, 2000
4. Kimball P, Elswick RK, Shiffman M: Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 65:510-516, 2001
5. Fried MW, Shiffman ML, Sterling RK, Weinstein J, Crippin J, Garcia G, Wright TL, Conjeevaram HS, Reddy KR, Peter J, Cotsonis GA, Nolte FS: A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 95:3225-3229, 2000
6. Fried MW: Advances in therapy for chronic hepatitis C. Clin Liver Dis 5:1009-1023, 2001
7. Shiffman ML: Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 19 (suppl 1):25-33, 1999
8. Layden TJ, Lam NP, Wiley TE: Hepatitis C viral dynamics. Clin Liver Dis 3:793-810, 1999
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107, 1998
10. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26:226-231, 1997
11. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW: Ultrarapid hepatitis C virus clearance by daily high-dose interferon in nonresponders to standard therapy. J Hepatol 28:960-964, 1998
12. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, Turner JR, Janisse JJ, Massanari M, Mutchnick MG: African Americans with genotype 1 treated with interferon for chronic hepatitis Chave a lower end of treatment response than Caucasians. J Viral Hepat 8:264-269, 2001
13. Wiley TE, Mika BP, McCarthy ME, Layden TJ: Pre-treatment differences between HCV-infected African American and non-African American patients. Hepatology 30:265A, 1999
14. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562, 1999
15. Kaufman JS, Cooper RS: Commentary: considerations for use of racial/ethnic classification in etiologic research. Am J Epidemiol 154:291-298, 2001
16. Cooper RS, Freeman VL: Limitations in the use of race in the study of disease causation. J Natl Med Assoc 91:379-383, 1999
17. Witzig R: The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med 125:675-679, 1996
18. Senior PA, Bhopal R: Ethnicity as a variable in epidemiological research. BMJ 309:327-330, 1994
19. Lindsay KL, McHutchison JG, Ling M-H, Albrecht JK: Response to PEG-IFN a2b (PEG-Intron) in blacks and hispanics with HCV is higher than with standard IFN a2b (IFN). Hepatology 32:347A, 2000
20. Shiffman ML, Fromm H, Mills P, Moonka Dk, Fried MW, Berg C, Sherman M, Coleman S, Marsano LS, Reddy KR, Brunda MJ, De Pamphilis J: Enhanced efficacy of pegylated (40kda) interferon alfa-2a (Pegasys) compared with interferon alfa-2a (Roferon-A) for chronic hepatitis C in blacks. Hepatology 32:348A, 2000